Schizophrenia has existed for as long as people have existed, but the diagnosis is surprisingly young. In 1893 nobody used the word. By 1911 it was a working clinical concept. By the 1980s it had become the central psychiatric disorder of the modern era, around which entire research institutes and pharmaceutical industries had organised. Knowing how that happened — and how much of the story is contested — is one of the more useful ways to understand what the diagnosis actually means today.
Modern schizophrenia is the product of a century of work by several generations of clinicians, repeatedly redefined as new evidence (and new medications) emerged.
Before the diagnosis: madness without a name
For most of recorded history, what we now call psychosis was understood through religious, supernatural, or moral frameworks. Greek physicians described conditions resembling psychosis; medieval European writers spoke of melancholia and mania. Hospitals like Bethlem in London (founded 1247) cared for people with severe mental illness without distinguishing schizophrenia from anything else. The 18th and 19th centuries saw the rise of "asylums" — large institutions that, at their best, gave people stable shelter, and at their worst, warehoused them for life.
Emil Kraepelin and "dementia praecox"
The first major step toward modern schizophrenia came from a German psychiatrist, Emil Kraepelin. In the 1890s, working with thousands of asylum patients, Kraepelin noticed that their illnesses fell into two broad patterns. One group had episodes of severe mood disturbance with periods of recovery between them — what he called manic-depressive insanity (now bipolar disorder). Another group developed psychotic symptoms in adolescence or early adulthood and had a deteriorating long-term course. He named the second pattern dementia praecox ("early-onset dementia").
Kraepelin's contribution was methodological: he insisted that diagnoses should be defined by the long-term course of an illness, not by a snapshot of symptoms. His framework still underpins how psychiatry organises the major mental disorders.
Eugen Bleuler renames it
The Swiss psychiatrist Eugen Bleuler disagreed with one important part of Kraepelin's framing: he had observed that many patients did not, in fact, deteriorate inevitably. In 1908 (and at length in his 1911 monograph) he proposed a new name — schizophrenia, from the Greek schizein (to split) and phren (mind). The "splitting" he described was not split personalities (a persistent confusion to this day) but a fragmentation between thought, feeling, and behaviour.
Bleuler also broadened the concept. He emphasised the "four As" — disturbances of association, affect, ambivalence, and autism (in his sense, a withdrawal into inner life). This wider definition helped some patients who would have been written off under Kraepelin's stricter criteria, but it also made schizophrenia easier to over-diagnose.
Kurt Schneider and the search for clear symptoms
By the mid-20th century, clinicians wanted more concrete diagnostic anchors. The German psychiatrist Kurt Schneider proposed a list of "first-rank symptoms" — experiences he believed pointed strongly to schizophrenia. They included hearing voices commenting on one's actions, thought insertion or broadcasting, and certain types of delusions. Schneider's list dominated diagnostic thinking through the 1970s and shaped the criteria in early DSM editions, although later research showed his "first-rank symptoms" were neither necessary nor specific to schizophrenia.
The asylum era and its failures
Through the first half of the 20th century, treatment options were minimal. Insulin coma therapy, prolonged sleep treatment, and lobotomy (developed in the 1930s) were tried with varying degrees of harm. Asylums grew enormous; many in the US held tens of thousands of patients. The brutality and futility of much of this care is well-documented in NIMH's institutional history.
Chlorpromazine and the antipsychotic revolution
In 1952, French researchers Jean Delay and Pierre Deniker reported that chlorpromazine — originally synthesised as an antihistamine — could dramatically reduce hallucinations and delusions. The drug was approved in the US in 1954 as Thorazine. For the first time, a medication actually moderated the symptoms of psychosis. State hospital populations in the United States dropped from over 500,000 in 1955 to under 50,000 by the late 1990s, although deinstitutionalisation also created new problems (homelessness, jail-as-treatment) that persist.
Over the next several decades, more antipsychotics followed: haloperidol in the 1960s, the second-generation drugs (clozapine, olanzapine, risperidone) from the 1970s onward, and long-acting injectables in more recent decades. Each generation traded one set of side effects for another.
DSM and the operationalised diagnosis
In 1980, the third edition of the Diagnostic and Statistical Manual of Mental Disorders (DSM-III) introduced explicit, criteria-based diagnosis. Schizophrenia became something a clinician could check off as a list, with required symptoms and durations. This made research enormously easier — clinicians in different countries could finally agree on who had the diagnosis. It also tightened criteria, sharply reducing the rate of schizophrenia diagnoses in the US (which had been notoriously over-diagnosed) and ending the era when "schizophrenia" sometimes functioned as a catch-all label.
DSM-5 (2013) and DSM-5-TR (2022) refined these criteria further and removed the old subtypes (paranoid, disorganised, catatonic, etc.) that had not held up well in research.
The biological era
Beginning in the 1970s, brain imaging and genetics began to reveal that schizophrenia is not a single disease but a syndrome with deep biological roots. Subtle differences in brain structure (slightly enlarged ventricles, reduced grey matter in certain regions) are statistically present but not diagnostically reliable. Genetic studies show that schizophrenia is highly heritable and involves the combined effect of many small-effect genes — see our overview of the genetic risk of schizophrenia.
Where we are now
Today's understanding sits closer to Bleuler than Kraepelin in one respect: outcome is variable. Long-term studies coordinated by the World Health Organization, including the famous WHO International Pilot Study of Schizophrenia, have shown that roughly a third of people experience substantial recovery, another third improve with episodic relapses, and a smaller group has a more chronic course. Treatment is increasingly multidisciplinary — combining medication, CBTp, family work, and supported employment.
What hasn't changed
For all the progress, several uncomfortable facts have stayed roughly stable since Kraepelin's time. About 1 in 100 people develop schizophrenia. Onset is usually in late adolescence or early adulthood. Negative and cognitive symptoms remain harder to treat than positive ones. Stigma persists. The history of schizophrenia is, in part, the history of psychiatry learning to be honest about how much it still does not know.
This article is for educational purposes only and is not medical advice, diagnosis, or treatment. Always consult a qualified mental health professional. If you or someone you know is in crisis, call or text 988 in the US, or your local emergency number.